MEDICATION ERRORS RELATING TO SIMILAR OR MISLEADING MANUFACTURER SPECIFIC DRUG PACKAGING AND LABELLING

M. JESKE 1, C. GEHMACHER 2, P. SALCHNER 1, M. ZEILER 1.
1 INNSBRUCK UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, INNSBRUCK, AUSTRIA.
2 INSTITUTE OF PHARMACY UNIVERSITY OF INNSBRUCK, PHARMACOLOGY AND TOXICOLOGY, INNSBRUCK, AUSTRIA.

BACKGROUND AND IMPORTANCE
- Pharmaceutical packaging is often associated with medication errors. Especially the so-called "look-alikes" and "sound-alikes" are challenging. While some countries have already tackled this problem and introduced appropriate legislation, no initiatives have yet been taken in Austria.

AIM AND OBJECTIVES
- This study aimed to analyze the pharmaceutical packaging of the University Hospital pharmacy’s product portfolio for similar or misleading manufacturer-specific drug packaging and labeling to determine whether there are security gaps in this regard.

MATERIAL AND METHODS
- The recommendations of the "Sound-alike - Look alike" (SaLa) working group founded by Swiss hospital pharmacists were used as criteria.
- Besides, the cases of near-misses reported in the Austrian Critical Incident Reporting System CIRSmedical.at were evaluated.

RESULTS
- A total of 1,139 secondary packaging and 1102 primary packaging for solid oral preparations, and 474 secondary packaging and 653 primary packagings for parenteral preparations were assessed.
- The evaluation of the manufacturer’s implementation shows an inconsistent fulfillment of the recommendations of the working group SaLa. Especially the labeling and appearance of the primary packaging of parenteral products are one of the biggest existing problems.

<table>
<thead>
<tr>
<th>primary packaging problem areas</th>
<th>%</th>
<th>comment  - risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>No use of color to increase safety</td>
<td>76,4</td>
<td>increasing the likelihood of confusion</td>
</tr>
<tr>
<td>Rotation necessary for reading</td>
<td>51,8</td>
<td>Label design not well thought out - overlooking relevant information is likely</td>
</tr>
<tr>
<td>Lack of indication of the total amount of active substance</td>
<td>32,6</td>
<td>Calculation necessary - risk of error increases</td>
</tr>
<tr>
<td>Lack of indication of concentration per volume</td>
<td>30,3</td>
<td>Making dose calculation more difficult - risk of error increases</td>
</tr>
<tr>
<td>Lack of readable contrast</td>
<td>21</td>
<td>Wrong use of color, transparent labels - overlooking relevant information is likely</td>
</tr>
<tr>
<td>Multiple concentration data</td>
<td>16,3</td>
<td>Incorrect dose calculation possible - risk of error increases</td>
</tr>
<tr>
<td>Lack of indication of the routes of administration</td>
<td>10</td>
<td>Lack of control option - incorrect application possible</td>
</tr>
</tbody>
</table>

- Bigest problem areas of the primary packaging of parenterals:

- Out of a total of 522 reports on CIRSmedical, 35 were relevant for the evaluation. CIRSMedical’s data confirms the main problem with parenteral products’ primary packaging and indicates an increased risk of medication errors caused by LASA’s in the anesthesia and intensive care sector.

CONCLUSION AND RELEVANCE
- Some companies’ pharmaceutical packaging is very well thought out, while labeling on ampoules is hardly legible in others.
- The results show the existing security gaps in the design of drug packaging, though generalization that all pharmaceutical companies have insufficiently labeled and designed pharmaceutical packaging is not possible.
- Still, many pharmaceutical companies tend to prioritize marketing considerations when selecting the design of labels and packaging and ignore human factors.
- Professionals, legislation, and the pharmaceutical industry must be involved to reduce medication errors caused by misleading manufacturer-specific drug packaging and labeling.

References:
2. Look Alike Sound Alike - gemeinsame Arbeitsgruppe der Stiftung Patientensicherheit Schweiz (patientensicherheit.ch)